Patrick Gaffney | Academic Influence

Patrick Gaffney 's AcademicInfluence.com Rankings

Patrick Gaffney

Anthropology

#1521

World Rank

#1980

Historical Rank

#682

USA Rank

Cultural Anthropology

#73

World Rank

#94

Historical Rank

#42

USA Rank

anthropology Degrees

Patrick Gaffney

Religious Studies

#2046

World Rank

#4219

Historical Rank

#735

USA Rank

Theology

#1349

World Rank

#3067

Historical Rank

#458

USA Rank

religious-studies Degrees

Download Badge

Anthropology
Religious Studies

Patrick Gaffney 's Degrees

PhD Anthropology University of Chicago
Masters Anthropology University of Chicago
Masters Theology University of Notre Dame
Bachelors Anthropology University of Notre Dame

Similar Degrees You Can Earn

Why Is Patrick Gaffney Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Patrick Daniel Gaffney is an American anthropologist, academic, translator, member of the Congregation of Holy Cross and the current Vice-Chancellor of Notre Dame University Bangladesh. Education and career He earned his PhD from the University of Chicago and has taught at the University of Notre Dame, USA, since 1980. For his academic work, he received Kaneb Teaching Award in 2001, and Reinhold Niebuhr Award in 2002. A polyglot fluent in Arabic, French, German, Dutch, Spanish, Italian, Russian, and a competent reader in Latin, Greek, Hebrew, Gaffney translated Renaissance of the East by Hans Fortmann in 1972 and With Open Hands by Henri Nouwen in 1973 from Dutch into English. An expert on Islam and Islamic culture, Gaffney authored The Prophet's Pulpit: Islamic Preaching in Contemporary Egypt in 1994 and co-authored Breaking Cycles of Violence: Conflict Prevention and Intrastate Crises in 1999.

(See a Problem?)

Patrick Gaffney 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques (2001) (535)
A novel site-targeted ultrasonic contrast agent with broad biomedical application. (1996) (400)
High‐resolution MRI characterization of human thrombus using a novel fibrin‐targeted paramagnetic nanoparticle contrast agent (2000) (233)
Improved molecular imaging contrast agent for detection of human thrombus (2003) (193)
Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles (2004) (184)
Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. (2008) (170)
Computed tomography in color: NanoK-enhanced spectral CT molecular imaging. (2010) (152)
Subunit structure of the plasmin-induced degradation products of crosslinked fibrin. (1973) (123)
The sulphite precipitation method for fibrinogen measurement; its use on small samples in the presence of fibrinogen degradation products. (1976) (121)
A Collaborative Study of a Proposed International Standard for Tissue Plasminogen Activator (t-PA) (1985) (114)
Fibrin crosslinks and lysis rates. (1979) (111)
Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. (1987) (106)
Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. (1983) (104)
Molecular photoacoustic tomography with colloidal nanobeacons. (2009) (100)
In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. (1998) (100)
In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla (2006) (97)
Collaborative Study of a Proposed International Standard for Plasma Fibrinogen Measurement (1992) (95)
Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. (2007) (94)
Targeted PARACEST nanoparticle contrast agent for the detection of fibrin (2006) (93)
Gadolinium‐modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging (2008) (89)
High-frequency ultrasonic detection of thrombi with a targeted contrast system. (1997) (89)
Conquering the dark side: colloidal iron oxide nanoparticles. (2009) (86)
Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. (1998) (85)
High Sensitivity: High-Resolution SPECT-CT/MR Molecular Imaging of Angiogenesis in the Vx2 Model (2009) (83)
Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. (2009) (80)
Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model (2000) (80)
Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. (2004) (79)
A structural aspect of human fibrinogen suggested by its plasmin degradation (1971) (77)
A Performance Evaluation of Commercial Fibrinogen Reference Preparations and Assays for Clauss and PT-derived Fibrinogen (2002) (75)
Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. (1991) (75)
A Collaborative Study to Establish the 2nd International Standard for Fibrinogen, Plasma (2000) (73)
Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model (2002) (68)
Distinction between fibrinogen and fibrin degradation products in plasma. (1975) (66)
Bioimmunoassay (BIA) of Tissue Plasminogen Activator (t-PA) and Its Specific Inhibitor (t-PA/INH) (1985) (65)
Comparative mapping of loci controlling winter survival and related traits in oilseed Brassica rapa and B. napus (2002) (63)
A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. (2011) (63)
Characterisation of a soluble D dimer-E complex in crosslinked fibrin digests. (1975) (62)
Problems in the assay of thrombin using synthetic peptides as substrates. (1977) (59)
Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. (2009) (59)
Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator. (1988) (55)
Fibrin Degradation Products (2001) (55)
Heterogeneity of human fibrinogen. (1971) (53)
Localisation of carbohydrate in the subunits of human fibinogen and its plasmin induced fragments. (1972) (53)
Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. (1980) (52)
Unreliability of Current Serum Fibrin Degradation Product (FDP) Assays (1985) (47)
Textilinin‐1, an alternative anti‐bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss (2009) (47)
Subunit relationships between fibrinogen and fibrin degradation products (1973) (47)
A Collaborative Study to Establish the 2nd International Standard for Tissue Plasminogen Activator (t-PA) (1987) (47)
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus. (1995) (46)
Fibrin subunits in venous and arterial thromboembolism. (1976) (45)
Synthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus. (2011) (43)
A Comparison of Pentosan Polysulphate and Heparin II: Effects of Subcutaneous Injection (1982) (42)
Exercise-Induced Fibrinolysis – Fact or Fiction? (1982) (42)
Evaluation of the Fibrin Binding Profile of two Anti-fibrin Monoclonal Antibodies (1996) (42)
Nature of the high molecular weight fraction of fibrinolytic digests of human fibrinogen. (1968) (40)
"Active" refuges can inhibit the evolution of resistance in insects towards transgenic insect-resistant plants. (2004) (39)
Molecular Imaging of Human Thrombus with Computed Tomography (2005) (39)
THE OCCURRENCE AND CLINICAL RELEVANCE OF FIBRIN FRAGMENTS IN BLOOD (1983) (39)
Plasminogen activators in human colorectal neoplasia. (1986) (38)
The role of the monocyte in the generation and dissolution of arterial and venous thrombi. (1998) (38)
A family of textilinin genes, two of which encode proteins with antihaemorrhagic properties (2002) (38)
Fibrin degradation products. A review of structures found in vitro and in vivo. (2001) (38)
Comparison of Textilinin-1 with Aprotinin as Serine Protease Inhibitors and as Antifibrinolytic Agents (2006) (37)
Thrombolytic Profiles of Clot‐Targeted Plasminogen Activators Parameters Determining Potency and Initial and Maximal Rates (1993) (36)
Identification of D-Dimer-E Complex in Disseminated Intravascular Coagulation (DIC) (1979) (36)
The Haemostatic Balance – Astrup Revisited (1999) (35)
Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen. (1992) (34)
The lysis of crosslinked human fibrin by plasmin yields initially a single molecular complex, D dimer-E. (1979) (28)
Molecular imaging of human thrombus with computed tomography. (2004) (27)
A novel serine protease inhibitor from the Australian brown snake, Pseudonaja textilis textilis: Inhibition kinetics (1995) (27)
The activation of human [Glu1]plasminogen by human single-chain urokinase (1988) (27)
Preparation and stability of a highly purified human thrombin standard. (1980) (27)
Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993) (1994) (26)
Giant fibrin fragments derived from crosslinked fibrin: structure and clinical implication. (1980) (26)
Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk. (1998) (26)
Monoclonal antibodies to crosslinked fibrin degradation products (XL‐FDP) I. CHARACTERIZATION AND PRELIMINARY EVALUATION IN PLASMA (1988) (25)
A Coagulant Enzyme from Gaboon-Viper Venom: Some Aspects of its Mode of Action (1973) (25)
Tissue plasminogen activators in breast cancer. (1987) (25)
Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin. (2002) (25)
Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator (2006) (25)
Breakdown products of fibrin and fibrinogen: molecular mechanisms and clinical implications (1980) (24)
Plasma Fibrinogen and its Fragments during Streptokinase Treatment (1974) (23)
LIPASE ACTIVITY IN SOMATIC CELLS FROM SEPARATOR SLIME. (1965) (23)
A monoclonal antibody which recognises an epitopic region unique to the intact fibrin polymeric structure (1993) (23)
The relationship between plasma vasopressin and changes in coagulation and fibrinolysis during hip surgery. (1988) (22)
D-dimer. History of the discovery, characterisation and utility of this and other fibrin fragments (1993) (22)
Temperature dependence of ultrasonic enhancement with a site-targeted contrast agent. (2001) (22)
Generation and partial characterization of five monoclonal antibodies with high affinities for fibrin (1993) (22)
Plasmin Potency Estimates: Influence of the Substrate Used in Assay (1981) (22)
An International Collaborative Study to Investigate Standardisation of Hirudin Potency (1993) (22)
The International and “NIH” Units for Thrombin - How Do They Compare? (1995) (21)
A Collaborative Study to Establish a Standard for High Molecular Weight Urinary-Type Plasminogen Activator (HMW/u-PA) (1990) (21)
Influence of various structural domains of fibrinogen and fibrin on the potentiation of plasminogen activation by recombinant tissue plasminogen activator (1989) (21)
Discussion on the meeting on ‘Statistical modelling and analysis of genetic data’ (2002) (21)
The molecular and functional condition of plasma fibrinogen during thrombolytic therapy with streptokinase (SK) (1973) (21)
Assay methodology for urokinase: its use in assessing the composition of mixtures of high- and low-molecular weight urokinase. (1981) (20)
Monoclonal Antibodies to Human Fibrin: Interaction with other Animal Fibrins (1996) (20)
Soluble high-molecular-weight E fragments in the plasmin-induced degradation products of cross-linked human fibrin. (1975) (20)
The binding of glu- and lys-plasminogens to fibrin and their subsequent effects on fibrinolysis. (1980) (20)
UROKINASE VERSUS TISSUE PLASMINOGEN ACTIVATOR IN PULMONARY EMBOLISM (1988) (20)
The Effect of Pentosan Polysulphate (SP54) on the Fibrinolytic Enzyme System - A Human Volunteer and Experimental Animal Study (1985) (20)
Interaction of heparin with fibrinogen using surface plasmon resonance technology: investigation of heparin binding site on fibrinogen. (1996) (19)
Imaging of human thrombi in the rabbit jugular vein: I: Comparison of two fibrin-specific monoclonal antibodies. (1989) (19)
Molecular aspects of fibrin clot solubilization. (1971) (19)
Distribution of lipase among components of a water extract of rennet casein. (1966) (18)
Fibrinolysis : current fundamental and clinical concepts (1978) (18)
Pesticide resistance: can we make it a renewable resource? (2001) (18)
Time-evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticulate contrast agent (2000) (17)
Non-enzymatic glucosylation of fibrinogen. (1981) (17)
Urokinase: the Enzyme Responsible for Invasion and Metastasis in Human Breast Carcinoma? (1987) (16)
Single shot intrasplenic immunization: an advantageous procedure for production of monoclonal antibodies specific for human fibrin fragments. (1984) (15)
The ability of fibrinogen fragments to support ADP-induced platelet aggregation. (1979) (15)
A neoantigenic determinant in the D-dimer fragment of fibrin. (2002) (15)
Unreliability of chromogenic substrates for assay of the clotting activity of thrombin. (1978) (15)
Terminology for Macromolecular Plasmic Derivatives of Crosslinked Fibrin (1987) (15)
Human serum cholinesterase. I. Partial purification andnature of the heterogeneity of this system. (1970) (15)
The relative inhibition by α2-antiplasmin and plasminogen activator inhibitor-1 of clot lysis in vitro (1990) (14)
Screening for Fibrin Specific Monoclonal Antibodies: The Development of a New Procedure (1992) (14)
Standard for Human Thrombin (1975) (14)
Letters to the EditorF.D.P. (1972) (14)
Differences between neonates and adults in tissue-type-plasminogen activator (t-PA)-catalyzed plasminogen activation with various effectors and in carbohydrate sequences of fibrinogen chains. (2001) (14)
Origin of urinary fibrin-fibrinogen degradation products in renal glomerular disease. (1979) (14)
A Pig Collagen Peptide Fraction. A Unique Material for Maintaining Biological Activity During Lyophilization and During Storage in the Liquid State (1996) (14)
Fibrin(-ogen) interactions with plasmin. (1977) (14)
Changes in fibrinolysis in the intensive care patient. (1987) (13)
Sensitive and direct assays for functionally active plasminogen activators (tissue-type and urokinase-type) in plasma. (1989) (13)
A Standard for Human Plasmin (1975) (13)
Heterogeneity of fibrin polymerization inhibitor. (1966) (13)
Time evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticulate contrast agent. (2000) (13)
The Rapid Fibrin Plate – a Method for Plasminogen Activator Assay (1977) (12)
High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery. (1997) (12)
Negative Cross-Resistance: History, Present Status, and Emerging Opportunities (2013) (12)
Roles for chloride ion and fibrinogen in the activation of [Glu1]plasminogen in human plasma. (1988) (12)
Haemoglobin Hammersmith (beta-42 (CDI) Phe replaced by ser). (1967) (11)
Deterministic modeling of negative cross-resistance strategies for use in transgenic host-plant resistance. (2000) (11)
Studies on the mechanism of binding of serpins and serine proteases. (1992) (11)
Hyper-susceptibility to deltamethrin in parats-1 DDT resistant Drosophila melanogaster (2004) (11)
Plasma levels of fibrin fragments in men with myocardial infarction. (1986) (11)
The distribution of carbohydrate in the plasmin resistant core fragments (D,E) of human fibrinogen. (1974) (10)
Activation of plasminogen as a feature in its assay. (1977) (10)
Plasminogen activators and inhibitors in amniotic fluid (1989) (10)
Tissue plasminogen activator for thrombolytic therapy: expectation versus reality. (1992) (10)
Fibrinolysis: Current Prospects (1988) (10)
A novel radioimmunometric approach to the assay of components of human haemostasis: 1. Assay of plasma fibrinopeptide A levels. (1980) (10)
Report of the Task Force on Standards for Thrombin and Thrombin-Like Enzymes (1977) (10)
A Collaborative Study to Establish the Second International Standard for Streptokinase (1990) (10)
A Collaborative Study to Establish an International Standard for Alpha-Thrombin (1992) (10)
Standards in Fibrinolysis – Current Status and Future Challenges (1995) (9)
International Collaborative Study on the Assay of Commercially Available High and Low Molecular Weight Urokinases (1981) (9)
Quantitative intravascular ultrasound. Demonstration using a novel site targeted acoustic contrast agent (1995) (9)
Characteristics of Lipase-Rich Fractions of Milk Protein (1968) (8)
The International Standard for Plasminogen Activator Inhibitor-1 (PAI-1) Activity (1996) (8)
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence? (1987) (8)
Thrombosis: a molecular approach to therapy (1981) (7)
Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system. (2000) (7)
Bioavailability in Rats of Human Recombinant Tissue Plasminogen Activator After Subcutaneous and Intramuscular Injection (1986) (7)
The influence of various combinations of plasminogen and streptokinase on fibrinolysis. (1981) (7)
The activation of human [Glu1]plasminogen by human single-chain urokinase. (1988) (7)
MOLECULAR ASPECTS OF FIBRINOLYSIS (1981) (7)
Negative Cross-Resistance: Past, Present, and Future Potential (2007) (7)
The Stability of Tissue Plasminogen Activator (t-PA) (1983) (7)
Urokinase and its receptor: marker of malignancy? (1994) (7)
International Collaborative Study for the Establishment of the Second International Reference Preparation of Plasmin (1983) (7)
Effects of early plasmin digests of fibrinogen on isometric tension development in isolated rings of rat pulmonary artery. (1996) (6)
Haemoglobin O Arab in Egypt and Aden: possible errors resulting from the use of haemoglobin variants as genetic markers in population surveys. (1967) (6)
Investigation by HPLC of the Catabolism of Recombinant Tissue Plasminogen Activator in the Rat (1988) (6)
Ultra-rapid preparation of milligram quantities of the purified polypeptide chains of human fibrinogen. (1994) (5)
Monoclonal antibodies for the detection of thrombosis. (1990) (5)
An in vitro circulation model for thrombosis; influence of circulating plasmas on the binding of monoclonal antibodies to human fibrin clots (1995) (5)
An experimental clot model in sheep; generation of a heterologous clot and its detection in vivo using venography and (125)I labelled fibrinogen. (2002) (5)
The effect of anticoagulation with subcutaneously delivered polyethylene glycol conjugated hirudin and recombinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model. (2004) (5)
FIBRIN FRAGMENTATION BY PLASMIN: MOLECULAR CONSIDERATIONS AND THEIR RELEVANCE TO DIC AND THROMBOSIS (1982) (5)
Detection of fibrin in canine neoplasia. (1996) (4)
Characterisation of the chains of human fibrinogen isolated by perfusion chromatography using fibrin specific monoclonal antibodies. (1995) (4)
Characterisation of the fibrinolytic enzymes associated with malignant invasion in carcinoma of the breast (1985) (4)
Snake venoms and haemostasis: some suggested mechanisms of action. (1979) (4)
Quantitative immuno-recognition by a radial diffusion technique. (1977) (4)
ANCROD AND ITS ACTIVITIES (1973) (3)
Enhancement of ultrasound reflectivity depends on the specific perfluorocarbons utilized to formulate nanoparticle emulsion contrast agents (2000) (3)
Residual enzyme activity in the serum of a homozygote for the silent pseudocholinesterase gene. (1969) (3)
Plasminogen activators in human colorectal neoplasia (1986) (3)
Presence of a fast-acting specific inhibitor of plasminogen activator in human parotid saliva. (1989) (3)
The D Dimer-E Complex and Its Aggregates in Crosslinked Fibrin Digests (1979) (3)
MOLECULAR PATHOLOGY OF THE MULTIPLE FORMS OF FIBRINOGEN AND ITS FRAGMENTS (1975) (3)
Plasminogen activation by recombinant tissue plasminogen activator and potentiation by fibrin: a refined kinetic analysis (1995) (3)
The Establishment of a Standard for Plasminogen (Glu-Type) (1984) (3)
Standardization of plasminogen assays. (1988) (3)
Increased release of tissue plasminogen activator and its inhibitor in human parotid saliva upon stimulation. (1992) (3)
SENSITIVE AND QUANTITATIVE ASSAYS OF FUNCTIONALLY ACTIVE PLASMINOGEN ACTIVATORS IN PLASMA (1987) (3)
Further Physicochemical and Immunological Data Concerning the D-Dimer Complex (1977) (3)
Abstract 13493: Optimized Ruptured Plaque Detection with Ytterbium Nanocolloids and Spectral CT (2012) (2)
Proteinase‐like peptidase activities in malignant and non‐malignant gastric tissue (1986) (2)
2115 A novel targeted iron oxide nanocolloid agent for rapid detection of fibrin clots via T1 and T2 weighted MRI (2008) (2)
Some aspects of the molecular pathology of thrombosis and haemorrhage (1984) (2)
The Haemophiliac in the Eighties (1982) (2)
The influence of various combinations of plasminogen and streptokinase on fibrinolysis. II. A mechanistic study. (1982) (2)
Monoclonal Antibodies Against Fibrinogen, Fibrin and Their Fragments (1985) (2)
Rates and Mechanisms of Clot Lysis During Various Streptokinase (SK)-Plasminogen (PLGN) Treatments (1979) (2)
The Rapid Fibrin Plate – a Method for Streptokinase Assay (1975) (2)
Binding profiles of monoclonal antibodies with some animal fibrins (1992) (2)
Haemoglobin Sogn (β14 Arginine) A New Haemoglobin Variant (2009) (2)
A Simplified Method for Preparation of Highly Purified Human Thrombin (1977) (2)
The effect of pentosan polysulphate (SP54) on the human fibrinolytic system. (1986) (2)
The human pseudocholinesterase system. (1968) (2)
Abstract 2798: Fibrin-specific Spectral CT Molecular imaging Detects Ruptured Plaque without Calcium Interference (2008) (2)
Fibrinolysis. A delicate balance between enzymes and inhibitors (1992) (2)
DAIRY CATTLE DRINKING BEHAVIOR AND STRAY VOLTAGE EXPOSURE (1997) (2)
PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System (2000) (2)
The relationship of plasminogen activators and oncogenes to tumour invasion. (1990) (2)
86 Appraisal of an elisa procedure for the measurement of FDP in plasma (1988) (1)
Fibrin polymerisation. Evidence for a secondary polymerisation site on the carboxy terminal end of the AA chain using a human fibrin specific murine monoclonal antibody. (1996) (1)
The Action of Brinase in Vitro and in Vivo (1975) (1)
The Role of the Monocyte in the Generation and Dissolution of Arterial and Venous Thrombi (1998) (1)
[Hemoglobin E in a Congolese family]. (1968) (1)
ABSTRACTS FROM THE ANNUAL MEETING OF THE SURGICAL RESEARCH SOCIETY OF AUSTRALASIA, HELD IN WESTMEAD, SYDNEY, NSW, 15–17 SEPTEMBER 1988.: Systemic and tissue fibrinolysis in cutaneous ulcers (1989) (1)
Haemoglobin Sogn (beta 14 arginine) a new haemoglobin variant. (1968) (1)
Thrombolytic Profiles of Clot-Targeted Plasminogen Activators (2005) (1)
Thrombus-specific manganese-based “nanobialys” for MR molecular imaging of ruptured plaque (2012) (1)
Multiple Molecular Forms of Factor VIII (1975) (1)
77. A monoclonal antibody (MAb) to fibrin. Delineation of the epitope on the COOH terminal of the A??-chain and its use in a soluble fibrin assay (1998) (1)
In Vivo Penetration of Experimentally Produced Clots by Monoclonal Antibodies (2000) (1)
The pathobiochemistry of DIC. (1980) (1)
On the Origin of Plasma Plasminogen Activator in Man (1979) (1)
Development of an ELISA for the quantification of fibrin in canine tumours. (1999) (1)
IMMUNOASSAYS FOR SINGLE CHAIN URINARY-TYPE PLASMINOGEN ACTIVATOR (SCUPA) IN PLASMA AND IN CELL CULTURE SUPERNATANTS (1987) (1)
Stability of the glyco-enzyme tissue plasminogen activator studied by circular dichroism. (1995) (1)
A Comparison of Glu- and Lys-Plasminogens: Binding to Fibrin and Effect on Lysis Rates (1979) (1)
Fibrinolysis and the Thrombotic Tendency (1984) (1)
Abstract 18741: Spectral CT Imaging of Coronary Ruptured Plaque: A Step Closer to the Clinic (2010) (1)
11. Modulation of fibrin thickness and its relevance to the composition and lysis of fibrin (1996) (1)
Relevance of standards in fibrinolysis assays (1993) (1)
The effect of pentosan polysulphate (SP54) on the fibrinolytic enzyme system. An experimental animal study. (1986) (1)
Soluble fibrin. Characterisation and assay procedures. (1996) (1)
Plasminogen Activator Production By Malignant Human Cells: In Vivo And In Vitro Studies (1981) (1)
Distribution, purification, and kinetic behavior of components of the lipase system of skim milk / (1965) (1)
CATABOLIC BEHAVIOUR OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (R-t-PA) IN THE RAT (1987) (1)
The Effects Of Defibrination Procedures In Plasma At III Assays (1981) (1)
Exercise-Induced Fibrinolysis – Fact not Fiction – Reply (1983) (1)
CMR 2007: 1.02: Potential of streptokinase-activated nanoparticles for early revascularization in acute ischemic stroke (2007) (0)
100 The enhancement by various fibrinogen/fibrin domains of the activation of human plasminogen by tissue plasminogen activator (1988) (0)
Characterisation of a Soluble High Molecular Weight e Fragment Released by Plasmin from Cross-linked Fibrin (1975) (0)
Development of a site targeted acoustic contrast agent for improved medical ultrasonic diagnosis (1996) (0)
12. Development of a crosslinked soluble fibrin assay for use in human plasma (1996) (0)
Enhancement of the thrombolytic potency of single chain urokinase-type plasminogen activator by conjugation with a monoclonal antibody against polymerized fibrin (1991) (0)
Symposium — D-dimer from laboratory to bedside (1993) (0)
Proceedings: Multiple molecular forms of factor VIII. (1975) (0)
Abstract 16389: Molecular Imaging of Vulnerable Plaque With Thrombus-Specific NanoQ Copper Nanocolloids (2011) (0)
Abstract 333: Thrombus-specific Manganese Nanocolloids for MR Molecular Imaging of Ruptured Plaque (2009) (0)
Lipase. I. Characterization of the milk lipase system. (1970) (0)
246 Effectors of the activation of human [GLU1] plasminogen by recombinant tissue plasminogen activator (1988) (0)
Development Of A Rapid Immunometric Assay For The Factor VIII Antigens In Plasma (1981) (0)
Single step ultrarapid preparation of high purity chains of human fibrinogen (1994) (0)
Thrombolytic therapy (a review). (1996) (0)
15. Young (<43 years) male myocardial infarcts. Relevance of a number of assays in identifying this group after infarction (1996) (0)
List of Authors and Speakers (1988) (0)
Interaction of heparin with fibrinogen and some of its derivatives (1996) (0)
Abstract 20216: In vivo Mapping of Angiogenesis with Ultralow-Gadolinium Manganese Nanocolloids (2010) (0)
Fibrinogen and FDP-models of molecular pathology? (1973) (0)
Obituary: Dr Jean Choay 1923–1993 — An appreciation (1993) (0)
Biochemical aspects of fibrinogen, fibrin and FDP (1988) (0)
10. A national quality control approach to fibrin glues (1996) (0)
38. The use of purified domains and peptides of human fibrinogen to define the epitopes of four fibrin specific monoclonal antibodies (1996) (0)
Activation of the intrinsic fibrinolytic pathway with normal extrinsic responses in a patient undergoing gastric surgery (1990) (0)
Clinical Thrombosis. A Subunit Study of the Fibrin (1975) (0)
Potential value of monoclonal antibodies for the diagnosis and treatment of thrombosis (1990) (0)
The Sulphite Precipitation Method for Fibrinogen Measurement in Small Samples in the Presence of FDP’s (1975) (0)
The Effects of Arvin on Fibrin Formation and Cross-Linked Fibrin Degradation in Man (1988) (0)
Plasminogen activators inexperimental colorectal neoplasia: arole intheadenoma-carcinoma sequence? (1987) (0)
CMR 2005: 8.02: Fibrin-directed nanoparticles for combined imaging and local thrombolytic therapy (2006) (0)
Snake Venoms and Haemostasis: Suggested Mechanisms of Their Action In Vivo and In Vitro (1979) (0)
305 Mechanisms involved in the hormonal regulation of fibrinolysis during surgery (1988) (0)
Biological Activities Of Two Plasmin Preparations: Differential Binding To Fibrin And α2-antiplasmin (1981) (0)
Abstract 2237: Rapid T1w Molecular Imaging of Atherosclerotic Angiogenesis with Colloidal Iron Oxide Nanoparticle (2008) (0)
Plasminogen activators in human colorectal neoplasia (1986) (0)
Targeted acoustic contrast agents: New opportunities for ultrasound in medical diagnosis and therapy (1998) (0)
Abstract 594: Multicolored (Spectral) CT Molecular Imaging of Ruptured Plaque (2009) (0)
Abstract 10754: Energy-Resolved Computed Tomography for Coronary Fibrin Imaging with New Gold Nanobeacons (2011) (0)
Abstract 5580: Nanolytic Approach to Prompt Revascularization in Acute Ischemic Stroke (2009) (0)
Title Page / Table of Contents, Vol. 18, Supplement 1, 1988 (1988) (0)
Copper nanocolloids: a new thrombus molecular imaging approach to ruptured plaque (2012) (0)
A comparison of the plasminogen activator activity units of urinary-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA). (1992) (0)
39. Development and characterisation of a fibrin specific MAb-aprotinin construct (1996) (0)
The influence of fibrin assembly on its subsequent lysis (1995) (0)
Peptide heterogeneity in a preparation of synthetic fibrinopeptide B. (1984) (0)
Fibrin aggregation. early protofibril formation and its interactions with other components of haemostasis (1994) (0)
19. Fibrinogen to fibrin reactions. Their complexity revisited (1998) (0)
Letter: Ancrod and its activities. (1973) (0)
P51. Characterization of the epitope recognized by an antibody with specificity to human fibrin (1996) (0)
Routine measurement of fibrinogen concentration: Problems exaggerated (1993) (0)
76. Inhibitory properties of monoclonal antibodies to functional fragments of fibrin(ogen) (1998) (0)
The fate of the factor-13-mediated fibrin crosslinks during clot lysis. (1973) (0)
206 The generation of a fibrin specific monoclonal antibody using a unique “antigen-free” animal system (1988) (0)
323 A role for chloride ion and fibrinogen in the activation of [GLU1]plasminogen in human plasma (1988) (0)
Detection of fibrin in canine tumours — Its clinical relevance (1994) (0)
Roles for chloride ion and fibrinogen in the activation of [Glu']plasminogen in human plasma (plasminogen activation by tissue plasminogen activator/effectors of plasminogen activation/C1- inhibition of plasminogen activation/fibrinogen stimulation of plasminogen activation) (2003) (0)
D-dimer : from laboratory to bedside : an international symposium of the XIV ISTH Meeting, New York, July 1993 (1993) (0)
Contents, Vol. 10, 1981 (1981) (0)
Recent progress in blood coagulation and fibrinolysis : proceedings of the International Symposium 'Clot Formation and Lysis' held on March 21-22, 1997, Hamamatsu, Japan, as a satellite symposium of the 74th Annual Meeting of the Japanese Society of Physiology (1997) (0)
CMR2009: 9.04: Multicolored (spectral) CT molecular imaging: the next step in CT imaging (2009) (0)
37. Development of an ELISA for the detection and quantitation of fibrin in dog tumours (1996) (0)

This paper list is powered by the following services:

Other Resources About Patrick Gaffney

en.wikipedia.org

What Schools Are Affiliated With Patrick Gaffney ?

Patrick Gaffney is affiliated with the following schools: